The initial delivery system for Brilacidin for CV19 will be an IV based delivery similar to B-ABSSSI. There have been some posters for some reason comparing B-CV19 to B-OM which have different delivery systems and dosing requirements and is at best an apples to watermelon comparison. In the ABSSSI FDA trials a single dose of Brilacidin was comparable to a 7 day dose of Daptomycin. If Brilacidin approaches effectiveness in CV19 human trials compared to proven outstanding lab testing, we MAY see a regiment of 1-3 dosing protocol depending on the advancement or stage of the patient’s CV19 disease. This dosing protocol WOULD be half or less than half of the Remdesivir protocol of 6 treatments over a 5 day period.
Remdesivir is the only current FDA approved treatment for emergency use. The 4 day reduction in hospital stay is a huge improvement verses no other approved options. Remdesivir has not yet been proven to reduce mortality in CV19.
IF human trials with Brilacidin parallel outstanding lab testing results, Brilacidin will significantly leapfrog past Remdesivir and become the CV19 treatment of choice. Brilacidin has the unique combination of having anti-infective properties, immuno/anti-inflammatory properties and superior lab proven anti-viral properties against CV19.
Proposed Remdesivir pricing is $390 per vial or $2,340 per patient with 6 treatments. I have NO IDEA what IPIX’s Brilacidin pricing model will be but with less dosing needed, I would EXPECT Brilacidin to not only be a more effective treatment but will MOST LIKELY be a less expensive per patient CV19 treatment compared to Remdesivir.
Having NO IDEA what the pricing model, dosing protocol or profit margins will be, a potential revenue or earnings model is at best a WAG. With that said IF a Brilacidin CV19 treatment had a similar price per vial and a 3 treatment protocol it would be half the $2,340 per patient or $1,170 per patient. Another WAG is a 50% profit margin GUESSTIMATE after manufacturing and distribution which would be a profit of $585 per patient. That would be $585M in NET EARNINGS for every 1M patients treated. This example has too many unknowns to be a valid guesstimate but if Brilacidin does indeed become the GOLD STANDARD for CV19 treatment the numbers will be staggering.
Remdesivir is the only current FDA approved treatment for emergency use. The 4 day reduction in hospital stay is a huge improvement verses no other approved options. Remdesivir has not yet been proven to reduce mortality in CV19.
IF human trials with Brilacidin parallel outstanding lab testing results, Brilacidin will significantly leapfrog past Remdesivir and become the CV19 treatment of choice. Brilacidin has the unique combination of having anti-infective properties, immuno/anti-inflammatory properties and superior lab proven anti-viral properties against CV19.
Proposed Remdesivir pricing is $390 per vial or $2,340 per patient with 6 treatments. I have NO IDEA what IPIX’s Brilacidin pricing model will be but with less dosing needed, I would EXPECT Brilacidin to not only be a more effective treatment but will MOST LIKELY be a less expensive per patient CV19 treatment compared to Remdesivir.
Having NO IDEA what the pricing model, dosing protocol or profit margins will be, a potential revenue or earnings model is at best a WAG. With that said IF a Brilacidin CV19 treatment had a similar price per vial and a 3 treatment protocol it would be half the $2,340 per patient or $1,170 per patient. Another WAG is a 50% profit margin GUESSTIMATE after manufacturing and distribution which would be a profit of $585 per patient. That would be $585M in NET EARNINGS for every 1M patients treated. This example has too many unknowns to be a valid guesstimate but if Brilacidin does indeed become the GOLD STANDARD for CV19 treatment the numbers will be staggering.
17
